CMET-22. CAPMATINIB (INC280) IN METΔEX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY

BACKGROUND: Capmatinib is a highly potent, selective MET-inhibitor known to cross the BBB, and intracranial activity with capmatinib has been previously reported. Updated results for overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and brain metastases (BM) a...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Heist, Rebecca S, Seto, Takashi, Han, Ji-Youn, Reguart, Noemi, Garon, Edward B, Groen, Harry J M, Tan, Daniel S W, Hida, Toyoaki, de Jonge, Maja, V Orlov, Sergey, Smit, Egbert F, Souquet, Pierre-Jean, Vansteenkiste, Johan, Le Mouhaer, Sylvie, Robeva, Anna, Waldron-Lynch, Maeve, Giovannini, Monica, Wolf, Juergen
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2019
Onderwerpen:
CNS Metastasis
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847109/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.223
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items